BridgeMD
New treatment option for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Official title Low Dose Epcoritamab Plus GemOx in R/R DLBCL
ClinicalTrials.gov ID: NCT07451652
What this study is testing
What is Epcoritamab?
Epcoritamab is an investigational medicine, given as an once-weekly, being studied as a potential treatment for relapsed/refractory diffuse large b cell lymphoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- people with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to...
- ECOG 0-2
- Women of reproductive age who agree on getting a contraceptive method
- people who fulfill Lugano´s criteria for disease activity
- people who voluntarily accept to participate in this study
You likely can't join if
- Active bacterial, viral or fungal infection
- people who have already received an autologous o allogeneic stem cell transplantation
- people with other active neoplasias
- people with end-stage failure
The study team makes the final eligibility decision.
Where it's taking place
- Monterrey, Nuevo León, Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Monterrey, Nuevo León, Mexico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.